IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) was upgraded by equities researchers at The Goldman Sachs Group to a “strong-buy” rating in a report issued on Friday, Zacks reports.
A number of other research firms have also weighed in on IDXX. KeyCorp started coverage on IDEXX Laboratories in a research note on Monday, October 12th. They set a “sector weight” rating for the company. Citigroup upped their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. JPMorgan Chase & Co. dropped their target price on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a report on Friday. UBS Group raised their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $744.09.
Get Our Latest Analysis on IDXX
IDEXX Laboratories Stock Performance
NASDAQ IDXX traded up $13.18 on Friday, reaching $560.36. 708,811 shares of the company’s stock traded hands, compared to its average volume of 531,547. The firm has a market cap of $44.15 billion, a price-to-earnings ratio of 39.41, a P/E/G ratio of 2.92 and a beta of 1.55. The stock has a 50 day moving average price of $534.22 and a 200-day moving average price of $551.84. IDEXX Laboratories has a fifty-two week low of $500.61 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm’s revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the company earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts predict that IDEXX Laboratories will post 14.80 EPS for the current fiscal year.
Insider Activity
In other news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director directly owned 9,568 shares of the company’s stock, valued at $5,090,941.44. This represents a 18.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.79% of the stock is currently owned by insiders.
Hedge Funds Weigh In On IDEXX Laboratories
A number of large investors have recently bought and sold shares of the business. Aurora Investment Managers LLC. acquired a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $2,442,000. National Pension Service lifted its position in shares of IDEXX Laboratories by 5.6% during the 2nd quarter. National Pension Service now owns 129,305 shares of the company’s stock valued at $68,071,000 after buying an additional 6,885 shares in the last quarter. NewEdge Advisors LLC grew its stake in IDEXX Laboratories by 60.9% in the 1st quarter. NewEdge Advisors LLC now owns 15,221 shares of the company’s stock valued at $8,552,000 after acquiring an additional 5,761 shares during the period. Arizona State Retirement System grew its stake in IDEXX Laboratories by 4.9% in the 2nd quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock valued at $11,988,000 after acquiring an additional 1,074 shares during the period. Finally, SVB Wealth LLC grew its stake in IDEXX Laboratories by 17.4% in the 1st quarter. SVB Wealth LLC now owns 7,335 shares of the company’s stock valued at $4,121,000 after acquiring an additional 1,089 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.
About IDEXX Laboratories
IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.
IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.
See Also
- Five stocks we like better than IDEXX Laboratories
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
